Evaluation of four once-daily aminoglycoside dosing nomograms

Pharmacotherapy

Volumn 22, Issue 9, 2002, Pages 1077-1083

  Wallace, Allison Wood ^a   Jones, Matthew ^a   Bertino, Joseph S ^a,b  

^a BASSETT HEALTHCARE   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; GENTAMICIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; RETROSPECTIVE STUDY; ADULT; AGED; ALGORITHM; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INTENSIVE CARE UNIT; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBIOTICS, AMINOGLYCOSIDE; BACTERIAL INFECTIONS; FEMALE; GENTAMICINS; HUMAN; INTENSIVE CARE UNITS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; REFERENCE STANDARDS; SOFTWARE; ANTI-BACTERIAL AGENTS; HUMANS; MIDDLE AGED;

EID: 0036708207     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.13.1077.33529     Document Type: Article

References (29)

1. Editorial response: Single daily dosing of aminoglycosides - A concept whose time has not yet come
2. Editorial response: Single daily dosing of aminoglycosides - A community standard?
3. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs
4. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentrations to minimal inhibitory concentration
5. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing
6. A dose-ranging study of gentamicin pharmacokinetics: Implications for extended interval aminoglycoside therapy
7. Gentamicin pharmacokinetics in patients with malignancies
8. Aminoglycoside monitoring: Timing of peak levels is critical
9. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate
10. Once-daily dosing of gentamicin: Experience with therapeutic drug monitoring and Bayesian pharmacokinetics
11. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides
12. Comparison of once-daily versus pharmacokinetics dosing of aminoglycosides in elderly patients
13. Once-versus twice-daily amikacin regimen: Efficacy and safety in systemic gram-negative infections
14. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections: A randomized trial
15. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy
16. Therapeutic drug monitoring of tobramycin: Once-daily versus twice-daily dosage schedules
17. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone
18. Experience with a once-daily aminoglycoside program administered to 2184 adult patients
19. Once-daily dosing of aminoglycosides: A consensus document
20. Prediction of creatinine clearance from serum creatinine
21. KINI: A one compartment intravenous pharmacokinetic analysis program
22. Aminoglycoside dosing weight correction factors for patients of various body sizes
23. National survey of extended-interval aminoglycoside dosing
24. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms
25. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
26. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring
27. Application of Bayes' Theorem to compare nephrotoxicity of aminoglycoside doses using extended interval, individualized pharmacokinetic monitoring, and multiple daily dosing